Merus Labs appoints Robert Bloch to the Board of Directors

– CANADA, Toronto – Merus Labs International Inc. (NASDAQ: MSLI; TSX:MSL) pleased to announce that Dr. Robert Bloch M.D. will join the Board of Directors effective today. Dr. Bloch is a European-based pharmaceutical industry veteran who has a proven track record of leading profitable growth in global markets. Dr. Bloch’s expertise in extracting value from established products and vast business development network is expected to accelerate Merus’ expansion plans.

Dr. Bloch has more than 15 years of leadership experience with global pharmaceutical companies, including 7 years at F. Hoffmann-La Roche, based in Switzerland, most recently as Vice President, Global Head – Established Products. At Roche he successfully led a multi-billion USD franchise and had considerable influence on the company’s overall strategic direction and operating performance. Before joining Roche, Dr. Bloch advanced through several leadership roles at Schering-Plough and Wyeth.

Dr. Bloch’s extensive experience strengthens Merus’ market knowledge and network in the European market. Dr. Bloch commented, “I believe Merus has established a strong foundation across Europe which sets the path for sustainable growth and value creation. I am extremely excited to join the team and contribute to Merus’ growth.” Michael Cloutier, Chairman of the Board added “We are thrilled to have Dr. Bloch join our Board. His background and market knowledge add new strength to our European market growth plans.”

Merus also announces that Dr. Ulrich Schoeberl, Head of European Operations will be leaving on April 30, 2015. “I would like to thank Ulrich for his contributions to our organization. I know I speak for the Merus team and Board of Directors in wishing Ulrich success with his future endeavors,” said Barry Fishman, Chief Executive Officer.

With the Merus European infrastructure solidly in place and the recent addition of a Head of Supply Chain for Europe, the commercial role will be re-focused on pipeline expansion and commercial optimization. Dr. Bloch’s intricate knowledge of the European established products market will be of great value during this transition period and beyond, as Merus executes its growth strategy.

About Merus Labs International Inc.

Merus Labs is a specialty pharmaceutical company focused on acquiring established products. The Company leverages its expertise in European and North American markets to optimize the value of underdeveloped pharmaceutical assets.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>